Track topics on Twitter Track topics that are important to you
SAN DIEGO — At the American College of Rheumatology Annual Meeting, Gerd R. Burmester, MD, spoke about the efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of the MONARCH trial.
Burmester said results showed that patients with rheumatoid arthritis had improved physical function when switched from adalimumab 40 mg monotherapy to sarilumab 200 mg every 2 weeks. Additionally, the researchers found the safety profile for this open-label extension trial was consistent with the safety profile found in the MONARCH trial.
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...